Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.67 |
| ▸ | TNKS | O95271 | 11/20 | 0.67 |
| ▸ | PARP1 | P09874 | 6/20 | 0.67 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.67 |
| ▸ | WNT3A | P56704 | 6/20 | 0.67 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.67 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.67 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.67 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783488 | 0.80 | TNKS2 (1.00) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL30870719 | 0.73 | TNKS2 (0.78) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL27438554 | 0.68 | TNKS2 (0.61) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL15105584 | 0.68 | PARP1 (0.57) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL30870677 | 0.67 | TNKS2 (0.75) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL27438538 | 0.67 | TNKS2 (0.58) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL7776852 | 0.66 | TNKS2 (0.73) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL27438107 | 0.66 | TNKS2 (0.82) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL27438444 | 0.65 | TNKS2 (0.80) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL15775354 | 0.65 | TNKS (0.62) | TNKS2TNKSPARP1PARP2WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147047-A1 | Methods of Treating Resistant Cancers | UNIVERSITY OF BALTIMORE, MARYLAND (US) | 2020-05-14 | — | — | US | claimed |
| US-10624949-B1 | Methods for treating diseases related to the wnt pathway | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2020-04-21 | — | — | US | claimed |
| WO-2018213748-A1 | METHODS OF TREATING RESISTANT CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-11-22 | — | — | WO | claimed |
| US-20150284683-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-10-08 | — | — | US | claimed |
| EP-2882848-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | Singapore Health Services Pte Ltd (SG) | 2015-06-17 | — | — | EP | claimed |
| WO-2014025315-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-02-13 | — | — | WO | claimed |
| EP-4689063-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING RPE CELLS | Stemcell Technologies Canada Inc. (CA) | 2026-02-11 | — | — | EP | disclosed |
| US-20250114331-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | UNIV JOHNS HOPKINS (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2024207102-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING RPE CELLS | STEMCELL TECHNOLOGIES CANADA INC. (CA) | 2024-10-10 | — | — | WO | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| EP-4376960-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | The Johns Hopkins University (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-10391168-B1 | Anti-CD70 combination therapy | UNIVERSITY OF BERN (CH) | 2019-08-27 | — | — | US | disclosed |
| WO-2018213748-A1 | METHODS OF TREATING RESISTANT CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018195450-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2017156350-A1 | METHODS OF CANCER TREATMENT | K-GEN, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20150284683-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-10-08 | — | — | US | disclosed |
| EP-2882848-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | Singapore Health Services Pte Ltd (SG) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014025315-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391168-B1 | Anti-CD70 combination therapy | ABL1, BCR, CD2BP2 | TNKS2 1492/4885TNKS 2446/4885PARP1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.